[Perspective of gene therapy in hyperlipoproteinemia].
Several experimental trials are under way to correct the deficiency of LDL receptor function known as Familial Hypercholesterolemia (FH) that develops devastating atherosclerosis leading to premature fatal coronary occlusion. Recently, a 28-year-old FH homozygous woman has received ex vivo autologous liver transplantation after transduction with retroviral vector expressing functional LDL receptors. The outcome is partially successful but is still controversial because of an argument that the apparent small decrease in the total plasma cholesterol level is not necessarily caused by the correction of the LDL receptor expression. In addition to retrovirus, adenovirus vector and non-viral methods are being employed as potential tools for FH gene therapy.
Ishibashi
S
S
3rd Department of Internal Medicine, Faculty of Medicine, University of Tokyo.
Yamada
N
N
D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000818:Animals; D005260:Female; D015316:Genetic Therapy / Q000639:trends; D005822:Genetic Vectors; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000235:genetics / Q000628:therapy*; D016031:Liver Transplantation; D051379:Mice; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic
D011973:Receptors, LDL